Taxotere Hair Loss Lawsuits Expected To Increase With Eight Defendants Added To MDL

   

Taxotere Hair Loss Lawsuits Already Filed Allege Women Who Receive The Chemotherapy Drug To Treat Breast Cancer Suffer From Alopecia

taxotere lawsuit taxotere hair-loss-lawsuit side effects hair lossThe number of Taxotere hair loss lawsuits filed may increase as eight manufacturers have been added to federal litigation. The Eight additional manufacturers are makers of the generic form of the Taxotere chemotherapy drug. There are currently over 1,000 Taxotere lawsuits filed on behalf of women who suffered permanent hair loss after taking the chemotherapy drug to treat breast cancer. The complaints accuse Taxotere’s developer, Sanofi-Aventis, and its subsidiaries of failing to warn doctors and their patients about the permanent hair loss side-effect. (In Re: Taxotere (Docetaxel) Products Liability Litigation – Taxotere Lawsuits – MDL 2740)

Docetaxel, the generic form of Taxotere, was added to the title of the federal Taxotere litigation which the U.S. Judicial Panel on Multidistrict Litigation (JPML) established in October. U.S. District Judge Kurt D. Engelhardt, who is managing the Taxotere multidistrict litigation (MDL) in the Eastern District of Louisiana, asked the panel if docetaxel cases can be included in the Taxotere litigation. Generic drug makers are typically not part of litigation involving original drug manufacturers. However, the JPML told Judge Engelhardt that cases involving docetaxel can be included. As a result, the following eight docetaxel manufacturers were added to the MDL:

• Accord Healthcare Inc.
• Actavis Pharma, Inc.
• Eagle Pharmaceuticals Inc.
• Hospira Worldwide, LLC
• McKesson Corporation
• NorthStar Rx LLC
• Sandoz Inc.
• Sun Pharma Global Inc.

In May, Judge Engelhardt established a procedure for streamlining the process for serving generic drug makers with docetaxel lawsuits. (In Re: Taxotere (Docetaxel) Products Liability Litigation – Taxotere Lawsuits – MDL 2740)

“We are pleased with the JPML’s decision to include both the brand name and generic form of Taxotere to allow more women to seek justice and compensation for their permanent hair loss and other side effects,” says Dr. François Blaudeau, founder of Southern Med Law, who is also a practicing attorney and an obstetrician/gynecologist.

The Taxotere attorneys at Southern Med Law are investigating Taxotere alopecia side-effects complaints after a growing number of women are suffering permanent hair loss while battling breast cancer. If you have been prescribed the Taxotere chemotherapy drug or docetaxel, the generic form of Taxotere, to treat breast cancer and have suffered permanent hair loss and other side-effects, you can arrange for a free, no-obligation legal evaluation by calling Southern Med Law today at 205-547-5525 or visit www.southernmedlaw.com for more information and news on upcoming meetings and filings.

Taxotere was approved by the U.S. Food and Drug Administration (FDA) in 1996 to treat patients with locally advanced or metastatic breast cancer after previous chemotherapy treatments had failed. Docetaxel and other generic drugs are approved through the FDA’s 505(b)(2) process, which modifies FDA-approved drugs that are already on the market. The federal regulatory agency approved generic forms of Taxotere from 2011 to 2015.
[fda.gov/downloads/aboutfda/reportsmanualsforms/reports/economicanalyses/ucm433875.pdf]

In 2008, Sanofi-Aventis released its GEICAM 9805 clinical study which showed that Taxotere improves Disease Free Survival in women with high risk node-negative breast cancer. Plaintiffs contend in their Taxotere lawsuits that Sanofi-Aventis omitted information from the study that found alopecia persisted in 10 years and 5 months of follow-up time and was observed to be ongoing in 9.2 percent of the patients taking Taxotere.
[news.sanofi.us/press-releases?item=118305]

Taxotere hair loss lawsuits contend that Sanofi-Aventis failed to adequately warn physicians, health care providers, and patients in the United States about the risk of permanent hair loss. The company, however, warned health care professionals and patients in the European Union, Canada, and other countries about the alopecia side effect, according to the complaints. (In Re: Taxotere (Docetaxel) Products Liability Litigation – Taxotere Lawsuits – MDL 2740)

About Southern Med Law And Filing A Taxotere Hair Loss Lawsuit

Led by Dr. François Blaudeau, an attorney and a practicing obstetrician/ gynecologist, the legal staff at Southern Med Law possesses a deep understanding of the complex medical and legal questions at issue in Taxotere Hair Loss Lawsuits. They are not afraid to take on the nation’s largest corporations in their pursuit of justice, and are committed to ensuring that all victims have access to the type of aggressive legal advocacy that assures success. To speak to one of the firm’s Taxotere Hair Loss lawsuit attorneys, please call 205-547-5525 or fill out the online form.

Southern Med Law
François M. Blaudeau, MD JD FACHE FCLM Esquire
2224 1st Avenue North
Birmingham, Alabama 35203
Phone: (205) 547-5525
Fax: (205) 547-5526
francois@southernmedlaw.com
Medical Negligence/MedicalDevice/Pharma/Qui Tam
www.southenmedlaw.com
Like us on Facebook
Follow us on Twitter

This entry was posted in Southern Med Law | Article. Bookmark the permalink.